Fractyl Health, Inc. ( (GUTS) ) just unveiled an announcement.
On April 1, 2025, Fractyl Health announced positive early data from the REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study, suggesting that their product Revita may help prevent weight regain after GLP-1 drug discontinuation. The study, which is more than 50% enrolled, showed that patients experienced minimal weight regain, reinforcing Revita’s safety and potential as a transformative option for weight maintenance. The company anticipates full enrollment by summer 2025 and a mid-point analysis in Q3 2025, highlighting a significant commercial opportunity in the obesity treatment market.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing innovative treatments for metabolic diseases such as obesity and type 2 diabetes. The company aims to transform the treatment of these conditions from chronic management to therapies that address the root causes of the diseases. Based in Burlington, MA, Fractyl Health’s lead product candidate, Revita, is designed to remodel the duodenal lining to reverse damage caused by high-fat and high-sugar diets.
YTD Price Performance: -44.13%
Average Trading Volume: 294,214
Technical Sentiment Signal: Strong Buy
Current Market Cap: $60.66M
Learn more about GUTS stock on TipRanks’ Stock Analysis page.